The proteomic response in glioblastoma in young patients

Ruth F. Deighton*, Thierry Le Bihan, Sarah F. Martin, Martin E. Barrios-Llerena, Alice M J Gerth, Lorraine E. Kerr, James McCulloch, Ian R. Whittle

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Increasing age is an important prognostic variable in glioblastoma (GBM). We have defined the proteomic response in GBM samples from 7 young patients (mean age 36 years) compared to peritumoural-control samples from 10 young patients (mean age 32 years). 2-Dimensional-gel-electrophoresis, image analysis, and protein identification (LC/MS) were performed. 68 proteins were significantly altered in young GBM samples with 29 proteins upregulated and 39 proteins downregulated. Over 50 proteins are described as altered in GBM for the first time. In a parallel analysis in old GBM (mean age 67 years), an excellent correlation could be demonstrated between the proteomic profile in young GBM and that in old GBM patients (r2 = 0.95) with only 5 proteins altered significantly (p < 0.01). The proteomic response in young GBM patients highlighted alterations in protein-protein interactions in the immunoproteosome, NFkB signalling, and mitochondrial function and the same systems participated in the responses in old GBM patients.

Original languageEnglish
Pages (from-to)79-89
Number of pages11
JournalJournal of Neuro-Oncology
Issue number1
Publication statusPublished - 18 May 2014

Keywords / Materials (for Non-textual outputs)

  • Clinical proteomics
  • Glioblastoma
  • Patient age


Dive into the research topics of 'The proteomic response in glioblastoma in young patients'. Together they form a unique fingerprint.

Cite this